GLP-1 Medications

Compounded Semaglutide: What to Know

During shortages of Ozempic and Wegovy, compounding pharmacies began producing semaglutide alternatives. Here is an honest look at what they are, the risks involved, and where things stand today.

Back to GLP-1 Resource
Medical Disclaimer: ShedPilot is a nutrition and wellness app, not a medical provider. This content is for educational purposes only. Always consult your healthcare provider before starting any medication or supplement.

What Is Compounded Semaglutide?

Compounded semaglutide refers to semaglutide produced by compounding pharmacies — specialized pharmacies that can create custom medications when FDA-approved versions are unavailable or when a patient needs a formulation not available commercially. During the periods when Ozempic and Wegovy were on the FDA drug shortage list (at various points between 2022 and 2024), compounding pharmacies were legally permitted to produce semaglutide for patients.

The Legal Landscape

Compounding is legal under US federal law when specific conditions are met — including the drug being on the official shortage list, the compound being made for an individual patient with a valid prescription, and the pharmacy being properly licensed. When Wegovy and Ozempic were removed from the official FDA shortage list in 2024, the legal basis for most compounded semaglutide evaporated. The FDA issued guidance stating that compounding of semaglutide should cease and pursued enforcement action against large-scale compounders.

As of 2025–2026, the FDA considers most compounded semaglutide to be in violation of federal law. If you are currently using a compounded version, consult your healthcare provider about transitioning to an approved medication.

Quality and Safety Concerns

Even when legally permissible, compounded medications carry inherent quality risks. Unlike FDA-approved medications, compounded drugs do not go through the same rigorous testing for potency, purity, and sterility. Reports of adverse events associated with compounded semaglutide — including hospitalizations due to dosing errors — were documented by the FDA. Some compounded products were found to use semaglutide salts rather than the base form used in approved medications, with unknown bioavailability differences.

Why People Sought Compounded Versions

Cost and access were the primary drivers. Brand-name Wegovy can exceed $1,000 per month without insurance. Compounded semaglutide was often available for $100–$300 per month. For patients who could not access or afford the brand-name medication, compounding appeared to offer a viable path.

What to Do If You Were Using a Compounded Version

Speak with your prescribing physician about transitioning to an FDA-approved medication. Manufacturer patient assistance programs, telehealth platforms with pharmacy partnerships, and employer health benefits may offer more affordable access than retail pricing suggests.

Fueling your GLP-1 journey starts here.

ShedPilot builds your personalized meal plan around your medication, goals, and dietary needs — automatically.

Download the App Free